|
1
|
Yan-Fang T, Zhi-Heng L, Li-Xiao X, Fang F,
Jun L, Gang L, Lan C, Na-Na W, Xiao-Juan D, Li-Chao S, et al:
Molecular mechanism of the cell death induced by the histone
deacetylase pan inhibitor LBH589 (Panobinostat) in Wilms tumor
cells. PLoS One. 10:e01265662015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cui M, Liu W, Zhang L, Guo F, Liu Y, Chen
F, Liu T, Ma R and Wu R: Over-expression of miR-21 and lower PTEN
levels in Wilms' tumor with aggressive behavior. Tohoku J Exp Med.
242:43–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Beckwith JB, Kiviat NB and Bonadio JF:
Nephrogenic rests, nephroblastomatosis, and the pathogenesis of
Wilms' tumor. Pediatr Pathol. 10:1–36. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schenk JP, Günther P, Schrader C, Ley S,
Furtwängler R, Leuschner I, Edelhäuser M, Graf N and Tröger J:
Childhood kidney tumors - the relevance of imaging. Radiologe.
45:1112–1123. 2005.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Routh JC, Grundy PE, Anderson JR, Retik AB
and Kurek KC: B7-h1 as a biomarker for therapy failure in patients
with favorable histology Wilms tumor. J Urol. 189:1487–1492. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Li Y, Ma F, Zhou H, Ding R, Lu B,
Zou L, Li J and Lu R: Inhibitory effect of Par-4 combined with
cisplatin on human Wilms' tumor cells. Tumour Biol.
39:10104283177166892017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wari MN, Vallonthaiel AG, Ahmed A, Saxena
D, Iyer VK, Mathur SR, Agarwala S, Bakhshi S, Srinivas V,
Chattopadhyaya P, et al: Glypican-3 mRNA expression level in Wilms
tumor: Correlation with histological type, stage, and outcome.
Pediatr Surg Int. 33:695–703. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu S, Liu G, Fu W, Hu J, Fu K and Jia W:
Axl promotes the proliferation, invasion and migration of Wilms'
tumor and can be used as a prognostic factor. Onco Targets Ther.
10:955–963. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baranwal S and Alahari SK: miRNA control
of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290.
2010.PubMed/NCBI
|
|
11
|
Liu J: Control of protein synthesis and
mRNA degradation by microRNAs. Curr Opin Cell Biol. 20:214–221.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harada K, Baba Y, Ishimoto T, Shigaki H,
Kosumi K, Yoshida N, Watanabe M and Baba H: The role of microRNA in
esophageal squamous cell carcinoma. J Gastroenterol. 51:520–530.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen ZL, Wang B, Jiang KW, Ye CX, Cheng C,
Yan YC, Zhang JZ, Yang Y, Gao ZD, Ye YJ and Wang S: Downregulation
of miR-199b is associated with distant metastasis in colorectal
cancer via activation of SIRT1 and inhibition of CREB/KISS1
signaling. Oncotarget. 7:35092–35105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Favreau AJ, McGlauflin RE, Duarte CW and
Sathyanarayana P: miR-199b, a novel tumor suppressor miRNA in acute
myeloid leukemia with prognostic implications. Exp Hematol Oncol.
5:42016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Zhou F, Yin L, Zhao L, Zhang Y and
Wang J: MicroRNA-199b targets the regulation of ZEB1 expression to
inhibit cell proliferation, migration and invasion in non-small
cell lung cancer. Mol Med Rep. 16:5007–5014. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Torres A, Torres K, Pesci A, Ceccaroni M,
Paszkowski T, Cassandrini P, Zamboni G and Maciejewski R:
Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma
coexists with increased expression of mTOR kinase in endometrioid
endometrial carcinoma. BMC Cancer. 12:3692012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang HF, Zhang YY, Zhuang HW and Xu M:
MicroRNA-613 attenuates the proliferation, migration and invasion
of Wilms' tumor via targeting FRS2. Eur Rev Med Pharmacol Sci.
21:3360–3369. 2017.PubMed/NCBI
|
|
22
|
Liu GL, Yang HJ, Liu B and Liu T: Effects
of MicroRNA-19b on the proliferation, apoptosis, and migration of
Wilms' tumor cells via the PTEN/PI3K/AKT signaling pathway. J Cell
Biochem. 118:3424–3434. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zeng H, Zhang Z, Dai X, Chen Y, Ye J and
Jin Z: Increased expression of microRNA-199b-5p associates with
poor prognosis through promoting cell proliferation, invasion and
migration abilities of human osteosarcoma. Pathol Oncol Res.
22:253–260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang C, Song B, Song W, Liu J, Sun A, Wu
D, Yu H, Lian J, Chen L and Han J: Underexpressed microRNA-199b-5p
targets hypoxia-inducible factor-1α in hepatocellular carcinoma and
predicts prognosis of hepatocellular carcinoma patients. J
Gastroenterol Hepatol. 26:1630–1637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou SJ, Liu FY, Zhang AH, Liang HF, Wang
Y, Ma R, Jiang YH and Sun NF: MicroRNA-199b-5p attenuates
TGF-β1-induced epithelial-mesenchymal transition in hepatocellular
carcinoma. Br J Cancer. 117:233–244. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sakaguchi T, Yoshino H, Yonemori M,
Miyamoto K, Sugita S, Matsushita R, Itesako T, Tatarano S, Nakagawa
M and Enokida H: Regulation of ITGA3 by the dual-stranded
microRNA-199 family as a potential prognostic marker in bladder
cancer. Br J Cancer. 116:1077–1087. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang C, Wang FB, Li Y and Zeng XT:
Down-regulation of miR-199b-5p is correlated with poor prognosis
for breast cancer patients. Biomed Pharmacother. 84:1189–1193.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fang C, Zhao Y and Guo B: MiR-199b-5p
targets HER2 in breast cancer cells. J Cell Biochem. 114:1457–1463.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shang W, Chen X, Nie L, Xu M, Chen N, Zeng
H and Zhou Q: MiR199b suppresses expression of hypoxia-inducible
factor 1α (HIF-1α) in prostate cancer cells. Int J Mol Sci.
14:8422–8436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koshizuka K, Hanazawa T, Kikkawa N, Arai
T, Okato A, Kurozumi A, Kato M, Katada K, Okamoto Y and Seki N:
Regulation of ITGA3 by the anti-tumor miR-199 family inhibits
cancer cell migration and invasion in head and neck cancer. Cancer
Sci. 108:1681–1692. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Araki K, Osaki M, Nagahama Y, Hiramatsu T,
Nakamura H, Ohgi S and Ito H: Expression of RUNX3 protein in human
lung adenocarcinoma: Implications for tumor progression and
prognosis. Cancer Sci. 96:227–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dodurga Y, Avci CB, Satiroglu-Tufan NL,
Tataroglu C, Kesen Z, Doğan ZO, Yılmaz S and Gündüz C: Detection of
deleted in malignant brain tumors 1 and runt-related transcription
factor 3 gene expressions in bladder carcinoma. Mol Biol Rep.
39:4691–4695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang Y, Tong D, Lou G, Zhang Y and Geng
J: Expression of RUNX3 gene, methylation status and
clinicopathological significance in breast cancer and breast cancer
cell lines. Pathobiology. 75:244–251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC,
Lu PJ and Hsiao M: Loss of RUNX3 expression correlates with
differentiation, nodal metastasis, and poor prognosis of gastric
cancer. Ann Surg Oncol. 16:1686–1694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zheng W, Zheng K, Zhong L, Li Q and Huang
Z: Expression of Runx3 and C-myc in human colorectal cancer. Nan
Fang Yi Ke Da Xue Xue Bao. 34:1042–1047. 2014.(In Chinese).
PubMed/NCBI
|
|
36
|
Jili S, Eryong L, Lijuan L and Chao Z:
RUNX3 inhibits laryngeal squamous cell carcinoma malignancy under
the regulation of miR-148a-3p/DNMT1 axis. Cell Biochem Funct.
34:597–605. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen F, Liu X, Cheng Q, Zhu S, Bai J and
Zheng J: RUNX3 regulates renal cell carcinoma metastasis via
targeting miR-6780a-5p/E-cadherin/EMT signaling axis. Oncotarget.
8:101042–101056. 2017.PubMed/NCBI
|
|
38
|
Kim BR, Kang MH, Kim JL, Na YJ, Park SH,
Lee SI, Kang S, Joung SY, Lee SY, Lee DH, et al: RUNX3 inhibits the
metastasis and angiogenesis of colorectal cancer. Oncol Rep.
36:2601–2608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li H, Li D and Meng N: Effects of RUNX3
mediated Notch signaling pathway on biological characteristics of
colorectal cancer cells. Int J Oncol. 50:2059–2068. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang
L, Le X, Yao J, Wu TT, Huang S and Xie K: Loss of RUNX3 expression
significantly affects the clinical outcome of gastric cancer
patients and its restoration causes drastic suppression of tumor
growth and metastasis. Cancer Res. 65:4809–4816. 2005. View Article : Google Scholar : PubMed/NCBI
|
